Geneos Therapeutics Secures $17 Million in Series A2 Financing to Advance Personalized Cancer Immunotherapy Platform
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
Elizabeth Skale
Geneos expands its Phase Ib/IIa clinical trial in lead indication for treating patients with advanced hepatocellular carcinoma
Geneos Therapeutics, Inc.
3675 Market Street, Suite 200, Philadelphia, PA 19104
Copyright © 2023 Geneos Therapeutics, Inc. All rights reserved. Privacy Policy
‡ GENEOS, GT-EPIC™ and the GENEOS logo are trademarks of Geneos Therapeutics, Inc. All other trademarks are the property of their respective owners.